Lymphedema
Primary and secondary lymphedema pathophysiology, staging, and multimodal management
Background
Lymphedema is common globally; contemporary estimates vary and are method-dependent.
Primary Lymphedema
- Congenital or genetic defects in lymphatic development.
- Milroy disease: congenital, vascular endothelial growth factor receptor 3 (VEGFR3) mutation.
- Meige disease: onset around puberty.
- Late-onset primary lymphedema (20–40 yrs).
- Management includes the use of non-pneumatic compression (NPC), which is endorsed for its clinical utility by the American Venous Forum (AVF) and the American Venous and Lymphatic Society (AVLS) .
Secondary Lymphedema
- Cancer-related: most common cause in developed countries.
- Breast cancer-related lymphedema (BCRL) (axillary lymph node dissection, radiation); early preventive interventions, including prospective surveillance and early compression therapy, are critical in reducing incidence .
- Gynecologic malignancies (pelvic node dissection).
- Prostate and urologic cancers.
- Socioeconomic disparities and barriers to care, such as race and insurance status, significantly influence the prevalence and severity of BCRL .
- Infectious:
- Filariasis (Wuchereria bancrofti) – leading global cause.
- Other:
- Trauma, chronic venous insufficiency (CVI) (see 13CVI), obesity, inflammatory conditions.
- Physical therapy remains a primary intervention for managing secondary lymphedema associated with breast cancer, with network meta-analyses confirming its effectiveness in reducing limb volume .
Pathophysiology
- Lymphatic transport failure → accumulation of protein-rich interstitial fluid.
- Chronic inflammation → fibroblast activation, adipose deposition, fibrosis.
- Progressive skin changes: hyperkeratosis, papillomatosis, lymphorrhea.
- Immunologic dysfunction: impaired dendritic/T-cell trafficking → recurrent cellulitis.
Stages (ISL classification)
- Stage 0: latent/subclinical.
- Stage I: pitting edema, reversible with elevation.
- Stage II: persistent swelling, fibrosis.
- Stage III: elephantiasis, skin thickening, recurrent infections.
Clinical Presentation
- Chronic, insidious swelling (usually limbs).
- Heaviness, tightness, decreased ROM.
- Pitting early, non-pitting later.
- Stemmer’s sign: inability to pinch skin at base of second toe/finger.
- Recurrent cellulitis/erysipelas.
- In advanced cases: elephantiasis, verrucous skin changes, ulcers.
Clinical
- History of surgery, radiation, infection.
- Staging by ISL criteria.
Imaging
Computed tomography (CT) has a limited role in lymphedema characterization but may help exclude alternative diagnoses such as 12VTE or underlying malignancy . The characteristic honeycomb appearance of lymphedematous tissue is more consistently demonstrated on magnetic resonance imaging (MRI), which provides detailed structural information regarding subcutaneous changes. Additionally, ultrasonography (US) is often used to evaluate skin thickness and exclude venous pathology, while lymphoscintigraphy remains the clinical gold standard for the functional assessment of lymphatic transport.
Conservative (cornerstone)
Complete decongestive therapy (CDT) remains the gold standard and first-line treatment for lymphedema, consisting of an intensive decongestive phase (short-stretch multilayer bandaging, manual lymphatic drainage (MLD), exercise, and skin care) followed by lifelong maintenance with appropriately fitted compression garments.
- Compression: Transition from bandaging to flat-knit garments. Typical compression targets are 20–30 mmHg for the upper limb and 30–40+ mmHg for the lower limb as tolerated. Treatment should be individualized based on disease stage, patient tolerance, and comorbidities.
- Exercise: Supervised, progressive resistance and low-impact aerobic activity are safe and recommended with compression in place to improve lymphatic pump function.
- Infection prevention: Meticulous skin care is essential to prevent dermatological complications. Prophylactic penicillin V should be considered for patients with recurrent cellulitis.
- Pharmacologic agents: No disease-modifying therapy is currently approved. Anti-inflammatory strategies (e.g., ketoprofen) have early-phase data but are not standard of care.
- Adjuncts: Intermittent pneumatic compression (IPC) may be considered for selected patients as an adjunct to CDT. Weight management, skin care, and prompt treatment of cellulitis are emphasized. Antibiotic prophylaxis should be considered for patients with recurrent episodes.
Surgical and Interventional
1. Physiologic microsurgery
- Lymphaticovenular anastomosis (LVA): Best suited for earlier, fluid-predominant disease. This technique aims to bypass obstructed lymphatics by creating anastomoses into venules.
- Vascularized lymph node transfer (VLNT): Considered for selected patients with recurrent infections or failure of complete decongestive therapy, often combined with ongoing compression therapy.
- The evidence base demonstrates volume reduction and decreased infection frequency, though heterogeneity in surgical techniques and outcome measures persists.
2. Reductive surgery
- Liposuction with continuous postoperative compression is effective for advanced fibroadipose enlargement. The Charles procedure (excisional debulking) is reserved for exceptional cases.
3. Image-guided lymphatic interventions
- Lymphatic embolization is established for treatment of lymphatic leaks (e.g., chylothorax) but is not indicated for extremity lymphedema. Lymphangioplasty for peripheral lymphedema remains investigational with limited supporting evidence.
4. Medical therapy
- No pharmacologic cure is currently approved. Early-phase clinical data support anti-inflammatory modulation (e.g., ketoprofen), but routine use is not yet recommended.
Follow-up
- Lifelong compression and CDT adherence.
- Imaging surveillance after microsurgical reconstruction.
- Prompt antibiotics for cellulitis.
- Patient education critical for compliance.
Guidelines
Clinical practice guidelines provide evidence-based frameworks for the management of vascular pathologies. For lower extremity peripheral artery disease (PAD), the 2024 American College of Cardiology (ACC)/American Heart Association (AHA)/Society for Vascular Surgery (SVS) guideline offers updated recommendations for screening, diagnosis, and longitudinal management . A systematic review of global PAD guidelines has emphasized the need for high-quality, standardized approaches to screening and diagnosis, noting variations in current international recommendations .
In the management of lymphedema, specific pharmacological interventions have been evaluated: Rockson SG, et al. Pilot study of ketoprofen in lymphedema. JCI Insight. 2018. PubMed.
Risk stratification and incidence of cancer-related lymphedema
Breast cancer-related lymphedema (BCRL) incidence varies by axillary management and radiation exposure. Risk is higher after axillary lymph node dissection (ALND) compared to sentinel node biopsy. Obesity and infection further increase risk. Prospective surveillance programs and early compression therapy are recommended for high-risk patients.
Differential diagnosis and objective limb measurement
The differential diagnosis includes lipedema, phlebolymphedema, 12deep venous thrombosis with venous insufficiency (see 13CVI), and myxedema. Standard objective measurement methods include tape-derived truncated cone volume calculation, perometry, and water displacement volumetry. Diagnostic thresholds are typically defined as a ≥10% volume difference or ≥2 cm circumference difference between limbs, and these measurements are used to track treatment response.
Antibiotic prophylaxis for recurrent cellulitis in lymphedema
Prophylactic penicillin V should be considered for patients experiencing two or more cellulitis episodes per year. The decision should involve shared decision-making with the patient and requires periodic re-evaluation of ongoing need.
Patient selection and expectations for lymphatic surgery
Surgical intervention is guided by International Society of Lymphology (ISL) staging and indocyanine green (ICG) lymphography patterns. Lymphaticovenular anastomosis (LVA) is best suited for earlier, fluid-predominant disease. Vascularized lymph node transfer (VLNT) is considered for selected patients who have failed complete decongestive therapy or experience recurrent infections. Liposuction is effective for advanced fibroadipose enlargement. All surgical interventions require ongoing compression therapy. Outcomes remain heterogeneous due to variation in surgical techniques, patient selection, and outcome measures, highlighting the need for standardized outcome reporting.
References
- 1.Jacobowitz GR et al. Non-pneumatic compression and its clinical utility in management of lymphedema. A position statement endorsed by the American Venous Forum and the American Venous and Lymphatic Society. J Vasc Surg Venous Lymphat Disord. 2025. PMID: 41271100.PubMed-indexed articleClinical practice guideline2025
- 2.
- 3.
- 4.
- 5.
- 6.
- 7.Annunziata G, et al. The Role of Physical Exercise as a Therapeutic Tool to Improve Lipedema: A Consensus Statement from the Italian Society of Motor and Sports Sciences (SISMeS) and the Italian Society of Phlebology (SIF). Curr Obes Rep. 2024. PMID: 38958868.PubMed-indexed articleClinical practice guideline2024
- 8.International Society of Lymphology. 2020 Consensus Document. *Lymphology*. 2020. PubMedPubMed-indexed article2020
The document attempts to amalgamate the broad spectrum of protocols and practices advocated worldwide for the diagnosis and treatment of peripheral lymphedema into a coordinated proclamation representing a "Consensus" of the international community based on various levels of evidence.
- 9.Mortimer PS, Rockson SG. New developments in clinical aspects of lymphatic disease. *J Clin Invest*. 2014. PubMedPubMed-indexed article2014
The manner in which new knowledge of lymphatic genes and molecular mechanisms has demonstrated that lymphatic dysfunction should no longer be considered a passive bystander in disease but rather an active player in many pathological processes is considered and, therefore, a genuine target for future therapeutic developments.
- 10.Rockson SG, et al. Pilot study of ketoprofen in lymphedema. *NEJM*. 2018. PubMedPubMed-indexed article2018
2 exploratory studies together support the utility of targeted antiinflammatory therapy with ketoprofen in patients with lymphedema, and highlight the promise of such approaches to help restore a failing lymphatic circulation.
- 11.Thomas KS, Crook AM, Nunn AJ, Foster KA, Mason JM, Chalmers JR, et al. Penicillin to prevent recurrent leg cellulitis. N Engl J Med. 2013;368(18):1695-1703.PubMed-indexed article2013
In patients with recurrent cellulitis of the leg, penicillin was effective in preventing subsequent attacks during prophylaxis, but the protective effect diminished progressively once drug therapy was stopped.
- 12.Basta MN, et al. Quantitative assessment of lymphedema treatments: systematic review. *Plast Reconstr Surg*. 2014. PubMedPubMed-indexed article2014
Adopting an abdominal wall procedure–specific quality-of-life assessment tool as the standard is strongly recommended to gain a comprehensive understanding of abdominal wall defects and repairs.
- 13.
- 14.Mihara M, et al. Lymphaticovenular anastomosis for lymphedema: clinical outcomes. *Plast Reconstr Surg*. 2012. PubMedPubMed-indexed article2012
The present study identified HCV NS2 as a potent interferon antagonist, and describes an explanation of how NS2 downregulates the major signaling pathways involved in the development of host innate antiviral responses.
- 15.
- 16.
- 17.DiSipio T, Rye S, Newman B, Hayes S. Incidence of unilateral arm lymphoedema after breast cancer: a systematic review and meta-analysis. Lancet Oncol. 2013;14(6):500-515.PubMed-indexed article2013
It is suggested that more than one in five women who survive breast cancer will develop arm lymphoedema and a clear need exists for improved understanding of contributing risk factors, as well as of prevention and management strategies to reduce the individual and public health burden of this disabling and distressing disorder.
Educational use only
AI assists this editorial workflow. Published updates are human-reviewed before publication.
Not intended to diagnose, monitor, predict, prognose, treat, or alleviate disease.
Verify clinically relevant information against primary sources and current guidelines.